Skip to content

Plecanatide

A 16-amino-acid copy of the gut hormone uroguanylin, changed at a single position, taken as a once-daily tablet for chronic constipation and constipation-predominant IBS — it works entirely inside the intestine and is never measurable in blood.

BStrongWell-Studied
Last updated 31 citations
TL;DR

Plecanatide (Trulance) is a copy of a natural gut hormone, taken as one 3 mg tablet a day for long-term constipation or constipation-type IBS. It makes the intestine release fluid, which softens stool and speeds things up, and because it stays inside the gut it does not show up in blood. Diarrhoea is the main side effect. It must never be given to a child under 6 — in young mice, it caused fatal dehydration.

What is Plecanatide?

Plecanatide is a synthetic version of uroguanylin, a hormone the small intestine makes to regulate how much fluid it secretes. With the exception of a single amino acid replacement, it is identical to the human hormone: 16 residues held in shape by two disulfide bridges, a molecular weight of 1,682 daltons, and the same target — guanylate cyclase-C, a receptor sitting on the luminal face of the intestinal lining. Activating that receptor raises cyclic GMP inside the cell, which opens the CFTR chloride channel, pushes chloride and bicarbonate into the bowel, draws water after them and speeds transit. It is one of very few peptides in this directory that works as a swallowed tablet, and the reason is that it is not meant to be absorbed: plecanatide and its active metabolite are not measurable in adult human plasma at the therapeutic dose. Sold as Trulance, it was approved by the FDA on 19 January 2017 for chronic idiopathic constipation and in 2018 for irritable bowel syndrome with constipation, at a single 3 mg once-daily dose for both.

What Plecanatide Is Investigated For

Plecanatide's two approved indications rest on four large, well-run phase 3 trials and roughly 3,900 randomised patients, and the results are consistent: it beats placebo on the FDA's composite responder endpoints for both chronic idiopathic constipation and IBS-C, improves stool frequency and consistency from the first week, and does so at a 3 mg dose that a 6 mg arm never improved on. The honest caveat is about positioning rather than efficacy. Plecanatide arrived five years after linaclotide with a mechanistic selling point — it copies uroguanylin, whose receptor binding is pH-sensitive, rather than a bacterial enterotoxin, and was therefore expected to be more physiological and less likely to cause diarrhoea. That claim has not survived scrutiny. An independent meta-analysis of 10,369 patients found no statistically significant difference between linaclotide and plecanatide in efficacy, in diarrhoea, or in withdrawals due to diarrhoea, and noted that the two development programmes had used different definitions of diarrhoea in the first place. A pooled analysis showed that taking acid-suppressing drugs, which should blunt a pH-dependent agonist, did not reduce plecanatide's efficacy at all. What remains genuinely distinctive is prosaic and useful: it is a crushable tablet with a once-daily single dose and no systemic exposure.

Chronic idiopathic constipation in adults (FDA indication)
Strong90%
Irritable bowel syndrome with constipation in adults (FDA indication)
Strong90%
Abdominal bloating and pain accompanying IBS-C
Moderate70%
An option for people who cannot swallow capsules, since the tablet can be crushed or given by feeding tube
Strong90%
Gentler on the bowel than linaclotide because of pH-dependent activity
Limited15%
Functional constipation outside the Western trial populations
Moderate70%

History & Discovery

Guanylate cyclase-C was first characterised not as a drug target but as the receptor hijacked by enterotoxigenic E. coli. The bacterium's heat-stable enterotoxin binds GC-C and floods the intestine with fluid, which is how travellers' diarrhoea works. In the 1990s the body's own ligands for the same receptor were identified — guanylin in the colon and uroguanylin in the small intestine — and the obvious therapeutic inversion followed: if a toxin causes diarrhoea by overactivating this pathway, a controlled agonist should treat constipation. Two companies pursued it from opposite directions. Ironwood built linaclotide from the bacterial enterotoxin scaffold and reached the market first, in 2012. Synergy Pharmaceuticals built plecanatide from uroguanylin, reasoning that copying the human hormone — with its characteristic pH-sensitive receptor binding, tuned to the mildly acidic proximal small intestine — would produce a more physiological drug with less tendency to overshoot into diarrhoea. The molecule, SP-304, differed from native uroguanylin at a single residue, chosen for stability. A first-in-human single-dose study published in 2013 established tolerability, a phase 2 trial established the dose range, and four large phase 3 trials followed: two in chronic idiopathic constipation and two identical trials in IBS-C. The FDA approved Trulance for chronic idiopathic constipation on 19 January 2017 under NDA 208745 and added the IBS-C indication in 2018. Commercially it went badly. Linaclotide had a five-year head start and overwhelming sales, the mechanistic differentiation did not translate into a demonstrable tolerability advantage, and an independent meta-analysis published in early 2018 — the year plecanatide gained its second indication — reported no significant difference between the two drugs on efficacy or diarrhoea, and pointed out that their trial programmes had used different definitions of diarrhoea in the first place. Synergy Pharmaceuticals filed for Chapter 11 bankruptcy protection in December 2018 and its assets, including all rights to plecanatide and its sibling molecule dolcanatide, were sold to Bausch Health in a court-supervised process completed on 6 March 2019. Trulance is now marketed by Bausch's Salix division, which is the sponsor of record in FDA's database. The drug itself has aged better than its company. It appears as a recommended option in the joint AGA-ACG chronic constipation guideline and the AGA IBS-C guideline, a separately sponsored phase 3 trial in Chinese patients with functional constipation replicated the effect in 2025, and a steady stream of post hoc analyses has mapped its performance by age, sex and symptom cluster. What has not survived is the original differentiating story. A pooled analysis showed acid-suppressing drugs do not reduce its efficacy, which is hard to reconcile with pH-dependence mattering clinically, and the 2026 meta-analyses continue to find the two GC-C agonists interchangeable.

How It Works

The lining of the small intestine carries a receptor on its inner surface whose job is to decide how much fluid to pour into the gut. The body's own signal for that receptor is a hormone called uroguanylin, released after eating. Plecanatide is a near-exact copy of uroguanylin in tablet form. When it reaches the intestine it switches that receptor on, the cells pump chloride and bicarbonate into the bowel, water follows by osmosis, and stool becomes softer and moves faster. The same signalling molecule the receptor produces, cyclic GMP, also appears to quieten the pain-sensing nerves in the gut wall, which is why the drug helps with the abdominal pain of IBS and not just with bowel frequency.

Plecanatide is a 16-amino-acid peptide, molecular formula C65H104N18O26S4 and molecular weight 1,682 daltons, with two disulfide bridges linking cysteines 4 to 12 and 7 to 15 — the same bicyclic architecture as native human uroguanylin, from which it differs by a single amino acid substitution. Both plecanatide and its active metabolite bind guanylate cyclase-C on the apical surface of intestinal epithelial cells. GC-C is a transmembrane receptor with intrinsic guanylate cyclase activity, so ligand binding directly generates cyclic GMP on both sides of the membrane. Intracellular cGMP activates protein kinase G II, which phosphorylates the cystic fibrosis transmembrane conductance regulator and drives chloride and bicarbonate efflux into the lumen; sodium and water follow, increasing luminal fluid and accelerating transit. Extracellular cGMP has a separate role: in animal models of visceral pain it reduces the firing of afferent pain fibres in the gut wall, which is the accepted explanation for why GC-C agonists improve abdominal pain as well as bowel frequency, and preclinical work with plecanatide and its sibling molecule dolcanatide showed attenuation of visceral hypersensitivity in rat models. The pharmacological difference from linaclotide lies upstream of all this. Linaclotide is derived from the E. coli heat-stable enterotoxin and binds GC-C in a pH-independent manner, whereas uroguanylin-based ligands bind preferentially at the mildly acidic pH found in the proximal duodenum — a property examined in computational receptor modelling and marketed as conferring a more physiological, region-restricted effect. The clinical data have not borne that out. Systemically, plecanatide is effectively absent: it is minimally absorbed, is not measurable in adult human plasma at the 3 mg dose, and is therefore not expected to cause fetal exposure in pregnancy or to participate in cytochrome-mediated drug interactions. The absence of systemic exposure also explains the paediatric warning: in juvenile animals, where GC-C expression is higher and systemic absorption was demonstrable, the same luminal secretion that softens an adult stool was lethal.

Evidence Snapshot

Overall Confidence80%

Human Clinical Evidence

Strong. Two phase 3 trials in chronic idiopathic constipation randomising 1,394 and 1,337 patients, two identical phase 3 trials in IBS-C randomising 2,189 patients between them, a phase 2 dose-ranging study, an open-label long-term safety study, and a 2025 phase 3 trial in Chinese patients with functional constipation. Independent meta-analyses, a network meta-analysis of all chronic constipation drugs, FAERS pharmacovigilance and two major society guidelines all cover the drug. Pooled and post hoc analyses addressing bloating, age, demographics and concomitant acid suppression are numerous enough that reading them requires care about which are prespecified.

Animal / Preclinical

Adequate and, in one respect, decisive. Rodent models established the secretory and transit effects and the attenuation of visceral hypersensitivity, and juvenile mouse toxicology produced the mortality finding that drives the boxed warning and the paediatric contraindication — a rare case of an animal study directly determining the label's most prominent text.

Mechanistic Rationale

Very strong for the secretory effect, which is the body's own uroguanylin pathway reproduced by a near-identical peptide, and reasonable for the analgesic effect, which rests on extracellular cGMP suppressing afferent firing in animal models. The specific claim that pH-dependent binding yields a clinical advantage over linaclotide is the weak link, and the acid-suppression analysis argues against it.

Research Gaps & Open Questions

What the current literature has not yet settled about Plecanatide:

  • 01Whether pH-dependent receptor binding confers any clinical advantage at all. It is the drug's entire mechanistic differentiation from linaclotide, two independent meta-analyses have found no difference in efficacy or diarrhoea, and a direct pharmacodynamic test using concomitant acid suppression found no loss of effect.
  • 02Whether plecanatide has a place in children and adolescents. Paediatric functional constipation is common and the boxed warning closes the door below six on the strength of juvenile mouse mortality, while the 6-to-18 avoidance rests on no human data whatsoever. Nobody has attempted to define a safe paediatric exposure.
  • 03Long-term efficacy beyond 12 weeks. The randomised data stop there, with longer tolerability from a single open-label extension, which is a thin evidence base for a maintenance treatment in a lifelong condition.
  • 04Whether the analgesic effect on abdominal pain is genuinely mediated by extracellular cGMP suppressing visceral afferents, or is a downstream consequence of improved transit. The preclinical evidence is suggestive and no human study has separated the two.
  • 05Which patients should receive a GC-C agonist rather than a cheap osmotic laxative or prucalopride. Network meta-analysis ranks the options but the guidelines still cannot identify who benefits most, so sequencing is empirical.
  • 06Why a flat dose-response exists. A 6 mg dose performed identically to 3 mg in four separate phase 3 trials, implying receptor saturation at the lower dose, but the consequence — no titration option for partial responders — has never been addressed by developing an intermediate strength or an alternative regimen.

Forms & Administration

One 3 mg tablet by mouth, once daily, with or without food — the same dose for both chronic idiopathic constipation and IBS-C, with no titration and no alternative strength. Tablets are normally swallowed whole. For adults who cannot manage that, the label provides tested alternatives: crush the tablet to a powder and mix it with one teaspoon of room-temperature applesauce, consumed immediately; or put the tablet in a cup with about 30 mL of room-temperature water, swirl gently for at least 10 seconds until it falls apart, and drink the whole contents at once, rinsing the cup with a further 30 mL if any residue remains. For a nasogastric or gastric feeding tube the water method is used with at least 15 seconds of swirling. No mixture may be stored for later, and no other food or liquid has been tested. A missed dose is skipped rather than doubled.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

3 mg once daily. There is one strength and no titration. A 6 mg arm was carried through all four phase 3 trials and never outperformed 3 mg, so it was not approved.

Frequency

Once daily, at any time of day, with or without food.

Timing Considerations

Time of day

Any time of day, consistently

Relative to meals

With or without food — unlike linaclotide, which is taken on an empty stomach

Relative to exercise

Not tied to exercise timing.

Concomitant acid suppression requires no change in dose or timing; a pooled phase 3 analysis found no loss of efficacy in patients taking it.

Cycle Length

Continuous for as long as the indication persists. Chronic idiopathic constipation and IBS-C are long-term conditions and plecanatide is a maintenance treatment, not a course. The randomised evidence runs to 12 weeks, with longer-term tolerability from an open-label extension study; benefit stops when the drug stops.

Protocol Notes

The practical character of plecanatide dosing is its simplicity, and the flat dose-response is the reason. One 3 mg tablet, same dose for chronic constipation and for IBS-C, no need to time it around meals, and nothing to titrate — which cuts both ways, because a patient troubled by diarrhoea at 3 mg has no lower step available and either tolerates it or stops. Most diarrhoea appears within the first four weeks and severe diarrhoea, affecting 0.6% of patients, typically within the first three days, so the first month is when patients should be told plainly what to watch for and instructed to suspend the dose and rehydrate if stools become severe. Missed doses are skipped, never doubled. For anyone who struggles with tablets, the label's crushing instructions are tested and specific: a teaspoon of room-temperature applesauce, or 30 mL of room-temperature water swirled for 10 seconds, consumed immediately and never stored. Patients on proton pump inhibitors or H2 blockers need no adjustment, despite the drug's pH-sensitive pharmacology. And the single most important dosing fact has nothing to do with adults: this drug is contraindicated under 6 years of age and should be avoided up to 18.

Plecanatide is a prescription medicine for chronic idiopathic constipation and IBS-C in adults. Constipation with alarm features — bleeding, weight loss, anaemia, a family history of colorectal cancer, or new onset after 50 — needs investigation before any drug is started. The boxed warning about paediatric dehydration is absolute for children under 6.

Timeline of Effects

Onset

Fast. Both pivotal constipation trials recorded significant increases in weekly spontaneous and complete spontaneous bowel movements beginning in week 1, and the effect on stool consistency appears equally early. For IBS-C the bowel component moves on the same schedule while the abdominal pain component builds more slowly — the composite responder definition requires both in the same week, which is part of why responder rates look modest next to the symptom-level improvements.

Peak Effect

Effects plateau rather than peak. Weekly bowel movement frequency rose in week 1 and was maintained through week 12 in both constipation trials, with no evidence of either escalation or tachyphylaxis across that period. Because the dose cannot be increased, what a patient has at four weeks is broadly what they will have at twelve. The adverse-effect timeline runs in the opposite direction: diarrhoea is front-loaded, with most cases in the first four weeks and severe cases usually within three days.

After Discontinuation

Return of symptoms. Plecanatide does not modify the underlying motility or sensory disorder; it supplies a secretory stimulus for as long as it is taken, has no systemic accumulation and a half-life measured in the gut rather than the plasma it never enters. Bowel habit reverts toward baseline within days of stopping, and there is no withdrawal phenomenon or rebound constipation described in the trial programme — simply the condition the patient started with.

Monitoring & Measurement

Bloodwork & Labs

  • •No routine laboratory monitoring is required — the drug has no measurable systemic exposure and no hepatic, renal or haematological signal
  • •Serum electrolytes and renal function if severe or prolonged diarrhoea occurs, particularly in elderly or frail patients where dehydration is the mechanism of harm
  • •Haemoglobin and ferritin at baseline where constipation is undiagnosed, as part of excluding a structural cause rather than monitoring the drug

Functional & Performance Tests

  • •A daily bowel diary recording complete spontaneous bowel movements, stool consistency on the Bristol scale and straining — the trials ran on exactly these measures and they remain the only real way to judge response
  • •Worst abdominal pain scored daily in IBS-C, since the composite endpoint requires improvement in pain as well as in bowel frequency and patients often report one without the other
  • •Bloating and abdominal distension, which have been the subject of several dedicated post hoc analyses and matter more to many patients than frequency does
  • •Colonoscopy or other structural evaluation where alarm features are present, before rather than during treatment

When to Test

Baseline symptom diary for one to two weeks before starting, so that a response can be distinguished from normal fluctuation. Review at 4 weeks, which captures both the onset of benefit — visible from week 1 in the trials — and the window in which almost all diarrhoea occurs. Review again at 12 weeks, the limit of the randomised evidence, to decide whether continued treatment is justified. Thereafter, periodic review of whether the drug is still doing anything.

Interpretation & Notes

Judging plecanatide honestly requires a diary, because the FDA composite endpoints it was approved on are strict and the headline responder rates — around 20% against 10% on placebo in chronic constipation — understate what individual patients often notice. A durable overall responder had to achieve at least three complete spontaneous bowel movements and an increase of at least one, in nine of twelve weeks including three of the last four; plenty of patients who improve meaningfully never clear that bar. Conversely, an improvement in the first week is not proof of drug effect in a condition with placebo response rates of 10% to 18%, which is why a pre-treatment baseline is worth the trouble. The practical monitoring question is almost always tolerability rather than efficacy: diarrhoea is front-loaded, severe diarrhoea typically appears within three days, and because there is no lower dose the decision is binary. Patients should start the drug knowing to suspend it and rehydrate if stools become severe, rather than discovering that instruction after the fact.

Common Questions

How is plecanatide different from linaclotide?

They hit the same receptor from different ancestries. Linaclotide is modelled on the heat-stable enterotoxin produced by E. coli — the molecule responsible for travellers' diarrhoea — and binds guanylate cyclase-C regardless of pH. Plecanatide copies uroguanylin, the body's own ligand, whose binding is pH-sensitive and maximal in the mildly acidic proximal small intestine, which was expected to concentrate the effect where the hormone normally acts and reduce runaway secretion further down. Clinically the distinction has not shown up. A meta-analysis of 15 trials and 10,369 patients found no significant difference in efficacy, diarrhoea or diarrhoea-related withdrawals between the two drugs, and the authors noted the trials had not even defined diarrhoea the same way. A more recent IBS-C meta-analysis put diarrhoea relative risks at 5.29 for plecanatide 3 mg and 6.20 for linaclotide 290 micrograms, with overlapping confidence intervals. The real differences are practical: plecanatide is one tablet at one dose for both indications and can be crushed; linaclotide comes in three strengths and should be taken on an empty stomach.

Why is there a boxed warning about children?

Because of what happened to young mice. Guanylate cyclase-C is expressed more intensely in the immature intestine, and a single oral dose of plecanatide killed juvenile mice at the human age equivalent of roughly one month to under two years, within 24 hours, apparently from dehydration caused by fluid secretion into the gut. The FDA label therefore contraindicates Trulance outright in anyone under 6 years old and instructs prescribers to avoid it between 6 and 18. No deaths occurred in older juvenile mice, but there are no paediatric efficacy or safety data in humans at all, so the avoidance stands on the combination of the animal signal and the empty human dataset. The mechanism is a class property, but the two labels have since diverged: linaclotide's boxed warning was narrowed to children under 2, and it now carries approved pediatric indications — irritable bowel syndrome with constipation from age 7 and functional constipation from age 2 — while Trulance remains contraindicated under 6 with use discouraged from 6 to 18.

Does the 6 mg dose work better than 3 mg?

No, and that is one of the more interesting things in the dataset. Both pivotal chronic constipation trials and both IBS-C trials ran 3 mg and 6 mg arms against placebo, and the two doses performed within a couple of percentage points of each other every time — 21.0% versus 19.5% in one constipation trial, 20.1% versus 20.0% in the other. Only 3 mg was approved and only 3 mg is marketed. A flat dose-response of that kind usually means the receptor is already saturated at the lower dose, which is consistent with a drug that acts locally on a luminal receptor rather than through a plasma concentration. It also means there is no upward titration to try if 3 mg does not work.

Will acid-reflux medication stop it working?

It does not appear to. This is a fair question precisely because plecanatide's differentiating claim is pH-sensitivity: if the drug needs a mildly acidic environment, a proton pump inhibitor ought to interfere. A pooled analysis of the two phase 3 constipation trials examined the 338 of 2,639 patients who were taking concomitant acid suppression and found response rates of 23.6% on 3 mg and 22.1% on 6 mg against 7.6% on placebo — essentially identical to the rates in patients not on acid suppression. No dose adjustment is advised, and the label places no restriction on co-administration. The more interesting implication is for the mechanism story rather than for prescribing: if blocking gastric acid changes nothing, the clinical relevance of pH-dependent binding is doubtful.

Can the tablet be crushed?

Yes, and the label gives explicit instructions — which is unusual and genuinely useful. For adults with swallowing difficulty, a tablet can be crushed to a powder and mixed with a teaspoon of room-temperature applesauce, or placed in a cup with about 30 mL of room-temperature water and swirled for at least 10 seconds until it disintegrates, then swallowed immediately. The same water method, swirled for 15 seconds, is used for administration through a nasogastric or gastric feeding tube. Mixtures must be consumed straight away and never stored, and no other soft food or liquid has been tested. Plecanatide can be taken with or without food, so there is no timing constraint to work around either.

Who Plecanatide Is NOT For

Contraindications
  • •Children under 6 years of age — an absolute contraindication carried in a boxed warning, based on deaths from dehydration in young juvenile mice given a single oral dose.
  • •Known or suspected mechanical gastrointestinal obstruction, where stimulating fluid secretion into an obstructed bowel risks perforation or worsening distension.
  • •Known hypersensitivity to plecanatide or to the tablet excipients, magnesium stearate and microcrystalline cellulose.
  • •Patients aged 6 to under 18 years, where use is to be avoided rather than formally contraindicated; there are no human safety or efficacy data in this group at all.
  • •Anyone unable to maintain adequate oral fluid intake, since every harm associated with this drug is mediated by intestinal fluid loss.
  • •Undiagnosed constipation with alarm features — rectal bleeding, iron deficiency anaemia, unintentional weight loss, new onset over the age of 50, or a family history of colorectal cancer — should be investigated rather than treated empirically.

Drug & Supplement Interactions

Plecanatide has an unusually empty interaction profile, and for a structural reason: it is minimally absorbed and neither the parent peptide nor its active metabolite is measurable in adult human plasma at the therapeutic dose, so there is essentially no systemic drug to interact with. It is not a substrate, inducer or inhibitor of cytochrome P450 enzymes, and no dose adjustment is required for hepatic or renal impairment. The one interaction worth examining was pharmacodynamic rather than pharmacokinetic, and it is instructive that it turned out not to exist. Because uroguanylin-type ligands bind guanylate cyclase-C preferentially at mildly acidic pH, proton pump inhibitors and H2 receptor antagonists were a plausible source of interference. A pooled analysis of the two phase 3 constipation trials specifically examined the 338 patients taking concomitant acid suppression and found response rates statistically indistinguishable from those not taking it — 23.6% versus 7.6% for placebo in the acid-suppressed group, closely mirroring the overall result. No restriction appears in the label. The remaining caution is additive rather than interactive: combining plecanatide with other laxatives, osmotic agents or prokinetics predictably increases the risk of diarrhoea and dehydration, and the sensible approach is to taper existing agents rather than stack them.

Safety Profile

Safety Information

Common Side Effects

Diarrhoea — the only adverse reaction reported in at least 2% of patients and more often than placebo, at 5% versus 1% in the pooled chronic constipation trialsAbdominal distension and bloatingAbdominal tenderness or painFlatulenceNauseaDizziness and sinusitis, reported at low rates in individual trials

Cautions

  • • Boxed warning: contraindicated in children under 6 years because of fatal dehydration in young juvenile mice, and to be avoided between 6 and under 18 years, where no human safety or efficacy data exist.
  • • Contraindicated in known or suspected mechanical gastrointestinal obstruction, where adding secretion to a blocked bowel is dangerous.
  • • Severe diarrhoea occurred in 0.6% of treated patients in both the chronic constipation and the IBS-C trial pools, typically within the first three days; the label instructs suspending the dose and rehydrating.
  • • Most diarrhoea appears within the first four weeks, so the early weeks are when patients most need to be told what to expect and when to stop.
  • • Discontinuation for adverse events ran at 4% against 2% on placebo in the constipation programme, almost entirely driven by diarrhoea.
  • • Dehydration risk is the mechanism of harm throughout — anyone unable to maintain fluid intake, including frail or elderly patients with intercurrent illness, needs closer attention than the low overall event rates suggest.
  • • There is no dose below 3 mg, so a patient who gets diarrhoea at the only marketed strength has nothing to step down to.

What We Don't Know

Systemic safety questions are unusually quiet here, for a structural reason: plecanatide and its active metabolite are not measurable in adult human plasma at the therapeutic dose, so most of the concerns that attach to peptide drugs — immunogenicity, organ exposure, drug interactions through hepatic metabolism — barely arise. What remains open sits elsewhere. Paediatric use is a genuine void rather than a resolved question: the contraindication under 6 rests on juvenile mouse mortality and the avoidance from 6 to 18 rests on no data at all. Long-term use beyond the 12-week trials is supported mainly by one open-label extension. Whether the pH-sensitivity that distinguishes plecanatide from linaclotide has any clinical meaning remains unsettled and, on current evidence, looks unlikely. A FAERS disproportionality analysis of 861 cases found diarrhoea, constipation, abdominal distension and treatment dissatisfaction among the commonest reported events, which mostly confirms the trials while illustrating how much real-world reporting is driven by the drug simply not working for a given patient.

Myths & Misconceptions

Myth

Plecanatide is gentler than linaclotide because it copies a human hormone.

Reality

That was the launch argument and the evidence does not support it. A meta-analysis of 15 trials and 10,369 patients found no statistically significant difference between the two drugs in efficacy, diarrhoea, or diarrhoea-related withdrawals, and noted that the two development programmes had used different definitions of diarrhoea — which can manufacture an apparent difference out of nothing. A 2026 IBS-C meta-analysis put diarrhoea relative risks at 5.29 for plecanatide and 6.20 for linaclotide, with overlapping confidence intervals.

Myth

It is an oral peptide, so some of it gets into the bloodstream.

Reality

Essentially none does. Plecanatide and its active metabolite are not measurable in adult human plasma at the 3 mg dose. The drug is designed to act on a receptor facing into the intestinal lumen, so absorption would be a defect rather than a requirement. This is why it has no meaningful drug interactions, no hepatic or renal dose adjustment, and a pregnancy risk summary resting on the absence of fetal exposure.

Myth

If 3 mg is not enough, the dose can be increased.

Reality

There is no higher dose. A 6 mg arm ran in all four phase 3 trials and matched 3 mg within a couple of percentage points each time, so only 3 mg was approved and only 3 mg is manufactured. A partial responder's options are adding or switching to a different mechanism, not escalating this one.

Myth

A proton pump inhibitor will stop plecanatide working.

Reality

It is a reasonable prediction from the pH-sensitive mechanism and it is wrong. Among 338 patients in the pooled phase 3 trials taking concomitant acid suppression, response rates of 23.6% on 3 mg and 22.1% on 6 mg against 7.6% on placebo were essentially identical to those in patients not taking acid suppressors. No dose change is needed.

Myth

The paediatric warning is a precaution because children were not studied.

Reality

It is a precaution because something specific happened. A single oral dose of plecanatide killed young juvenile mice — at the human age equivalent of about one month to under two years — within 24 hours, apparently from dehydration driven by intestinal fluid secretion, and guanylate cyclase-C is more highly expressed in the immature intestine. That finding produced an absolute contraindication under 6 years, printed in a boxed warning, not a routine 'safety not established' footnote.

Published Research

31 studies

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis

Systematic reviewPMID: 42934540

Efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) in patients with irritable bowel syndrome with constipation: a systematic review and meta-analysis of randomized controlled trials

Nine trials and 5,718 IBS-C patients, searched to September 2025 and declared free of commercial relationships. Both drugs beat placebo on the FDA composite endpoint — relative risk 1.63 for plecanatide 3 mg and 1.78 for linaclotide 290 micrograms — and both raised diarrhoea several-fold, at relative risks of 5.29 and 6.20 with overlapping confidence intervals. The modern confirmation that the two GC-C agonists are therapeutically interchangeable.

Systematic reviewPMID: 42038325

Real-World Safety Analysis of the Constipation-Predominant IBS Treatment Options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor

Pharmacovigilance studyPMID: 41625191

Efficacy and tolerability of plecanatide for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis

Systematic reviewPMID: 41604554

The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome

Post hoc analysisPMID: 41214272

Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Independent replication outside the original development programme, in a population where functional constipation phenotypes and dietary patterns differ from the US trials. Reproducing the effect in a separately sponsored Chinese phase 3 trial eight years after approval is a stronger validation of the drug than any number of post hoc analyses of the original data.

Phase 3 trialPMID: 40571893

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system

861 cases and 2,057 adverse event reports from FAERS between 2017 and mid-2024, with disproportionality and Weibull time-to-onset analysis. The commonest signals were diarrhoea, constipation, abdominal distension and dissatisfaction with treatment — the first three confirming the trials and the fourth a reminder that in functional bowel disease, a large share of real-world reporting is about a drug not working rather than causing harm.

Pharmacovigilance studyPMID: 39654622

Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation

Phase 3 analysisPMID: 38594429

Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials

Pooled analysisPMID: 37649852

Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials

Post hoc analysisPMID: 37332239

American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation

The current joint AGA-ACG guideline, and the document that sets plecanatide's actual clinical position: a recommended pharmacological option for chronic idiopathic constipation, alongside rather than ahead of linaclotide, prucalopride and the cheaper osmotic agents that remain first-line. Published simultaneously in two journals; this is the Gastroenterology version.

Clinical guidelinePMID: 37211380

Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide

Phase 3 analysisPMID: 37162147

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation

Clinical guidelinePMID: 35738724

Guanylin and uroguanylin: a promising nexus in intestinal electrolyte and fluid homeostasis

ReviewPMID: 35158329

The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials

A direct test of whether plecanatide's pH-sensitive binding matters in practice. Among 338 of 2,639 pooled trial patients taking concomitant acid suppression, response rates were 23.6% on 3 mg and 22.1% on 6 mg against 7.6% on placebo — statistically significant and essentially identical to the response in patients not on acid suppressors. Reassuring for prescribing, and quietly damaging to the mechanistic differentiation the drug was launched on.

Pooled analysisPMID: 35086735

Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older

Pooled analysisPMID: 32660770

Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial

Phase 2 trialPMID: 32185662

Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis

Places plecanatide within the whole chronic constipation armamentarium rather than against linaclotide alone — prucalopride, lubiprostone, polyethylene glycol, tegaserod and the GC-C agonists ranked together on FDA composite endpoints. The most useful single reference for a reader asking where a peptide tablet sits among much older and cheaper options.

Network meta-analysisPMID: 31474542

Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy

ReviewPMID: 30774407

Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation

ReviewPMID: 30649746

Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome

ReviewPMID: 30550753

Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation

ReviewPMID: 29942351

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models

Preclinical studyPMID: 29740204

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

Two identical trials, 2,189 patients randomised, supporting the 2018 IBS-C indication. Overall responders — requiring both a 30% reduction in worst abdominal pain and at least one extra complete spontaneous bowel movement in the same week, for 6 of 12 weeks — were 30.2% and 29.5% versus 17.8% on placebo in Study 1, and 21.5% and 24.0% versus 14.2% in Study 2. The gap between the two studies' placebo rates is a reminder of how much placebo response varies in functional bowel disease.

Phase 3 trialPMID: 29545635

Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis

The independent head-to-head analysis, and the one that undercuts plecanatide's marketing story. Fifteen trials and 10,369 patients across both drugs; after meta-regression adjusting for placebo event rate there were no statistically significant differences between linaclotide and plecanatide in odds of efficacy, odds of diarrhoea, or diarrhoea-related withdrawals. The authors also found, from FDA documents, that the two development programmes had used different definitions of diarrhoea — which is how an apparent tolerability advantage can appear without existing. No financial support.

Meta-analysisPMID: 29380823

Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study

Clinical trialPMID: 29343131

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation

The second pivotal constipation trial, 1,337 patients, and the source of the useful one-line description of the molecule: with the exception of a single amino acid replacement, plecanatide is identical to human uroguanylin. Durable responders were 20.1% on 3 mg and 20.0% on 6 mg against 12.8% on placebo, with diarrhoea at 3.2%, 4.5% and 1.3%. Improvements in stool frequency and consistency began in week 1 and held for 12 weeks.

Phase 3 trialPMID: 29147135

Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog

Mechanistic studyPMID: 28357122

Plecanatide: First Global Approval

ReviewPMID: 28255961

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation

The first pivotal constipation trial: 1,394 patients randomised to plecanatide 3 mg, 6 mg or placebo for 12 weeks. Durable overall complete spontaneous bowel movement responders were 21.0% and 19.5% against 10.2% on placebo, with weekly CSBM frequency rising 2.5 and 2.2 per week against 1.2. Diarrhoea occurred in 5.9% and 5.7% versus 1.3%. The two active doses are indistinguishable, which is why only 3 mg reached the market. Funded by Synergy Pharmaceuticals, with five authors its employees and stockholders.

Phase 3 trialPMID: 28169285

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses

Phase 1 trialPMID: 23625291

Quick Facts

Class
Guanylate Cyclase-C Agonist
Tier
B
Evidence
Strong
Safety
Well-Studied
Updated
Nov 2026
Citations
31PubMed

Also known as

TrulanceSP-304Uroguanylin AnalogGuanylate Cyclase-C Agonist

Tags

FDA-ApprovedGut HealthOral PeptideIBSConstipation

Related Goals

Gut & Inflammation

Evidence Score

Overall Confidence80%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.